Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.68 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716695 | 0.87 | HSD11B1 (0.61) | HSD11B1HSD11B2HDAC1KMT2A | |
| SCHEMBL3665770 | 0.87 | HSD11B1 (0.61) | HSD11B1HSD11B2HDAC1KMT2ANPC1 | |
| SCHEMBL3662022 | 0.86 | HSD11B1 (0.77) | HSD11B1HSD11B2KMT2AALDH1A1MEN1 | |
| SCHEMBL3668895 | 0.85 | HSD11B1 (0.59) | HSD11B1HSD11B2HDAC1 | |
| SCHEMBL3662780 | 0.84 | HSD11B1 (0.61) | HSD11B1HSD11B2HDAC1 | |
| SCHEMBL3662227 | 0.84 | HSD11B1 (0.67) | HSD11B1HSD11B2HDAC1 | |
| SCHEMBL3668822 | 0.84 | HSD11B1 (0.66) | HSD11B1HSD11B2NPC1RAB9AALDH1A1 | |
| SCHEMBL3659681 | 0.83 | HSD11B1 (0.62) | HSD11B1HSD11B2KMT2AALDH1A1 | |
| SCHEMBL3664798 | 0.83 | HSD11B1 (0.58) | HSD11B1HSD11B2HDAC1KMT2AALDH1A1 | |
| SCHEMBL3715925 | 0.83 | HSD11B1 (0.64) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459549-B1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-19 | — | — | EP | claimed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | claimed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | claimed |
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OXGR1 | HSD11B1 1963/4885HSD11B2 1686/4885HDAC1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.